Serum miR-455-5p and Cardiac Structure and Function Parameters in Patients With Hypertensive Heart Disease

Condition(s) studied

Study summary

Hypertensive heart disease (HHD) is the leading cause of mortality and morbidity worldwide. In 2017, the prevalence of HHD worldwide was 217.9 per 100,000 people, an increase of 7.4% over 1990, which has brought huge financial burden and social and economic losses to the world. Therefore, HHD is a major public health challenge worldwide. In our previous studies, we found that miR-455-5p, a microRNA, could functioned as an inducer to promote cardiac hypertrophy. Because cardiac hypertrophy was a common phenomenon in patients with HHD, so it is interesting to clarify whether miR-455-5p could be employed as a marker to indicate the function and/or structure of heart in the development of HHD. Thus, the purpose of this study was to collect blood samples of hypertensive patients, as well as analysis the correlation between serum miR-455-5p level and cardiac function. The research could help doctors better predict the course of hypertensive heart disease and provide more effective treatments for different patients.

Eligibility

Primary outcome measure(s)

• Measurement of serum miR-455-5p level — the miR-455-5p level is collected at week 0, 6, 12 and 24.
  concentration of microRNA-455-5p in 100ml serum was determined by Elisa assay.
• Measurement of LVPWd and LVPWs — the LVPWd and LVPWs are collected at week 0, 6, 12 and 24.
  left ventricular posterior wall thickness in diastole state and systole state are measured and recorded by echocardiography and its affiliated software.
• Measurement of LVIDd and LVIDs — the LVIDd and LVIDs are collected at week 0, 6, 12 and 24.
  left ventricular internal diameter in diastole state and systole state are measured and recorded by echocardiography and its affiliated software.
• Measurement of IVSTd and IVSTs — the IVSTd and IVSTs are collected at week 0, 6, 12 and 24.
  interventricular septum in diastole state and systole state are measured and recorded by echocardiography and its affiliated software.
• Calculation of LVMi — the LVMi is calculated at week 0, 6, 12 and 24.
  left ventricular mass index was calculated based on the formula: LVMi=LVM/BSA; For LVM, LVM(g)=0.8\*1.04\*\[(IVSTd+LVPWd+LVIDd)\^3-LVIDd\^3\]+0.6; For BSA, BSA=\[Body height (cm)\*Body weight (kg)/3600\]\^0.5； Diagnosis of LVH: LVMi(Male)\>115g/m2；LVMi(Female)\>95g/m2
• Measurement of LVEF — the EF is calculated at week 0, 6, 12 and 24.
  left ventricular ejection fraction are measured and recorded by echocardiography and its affiliated software. Generally, LVEF is range from 50% to 70% is regarded as normal. If LVEF less than 50%, the patient is suspected to suffered cardiac systolic dysfunction.
• Measurement of FS — the FS is calculated at week 0, 6, 12 and 24.
  Fractional shortening are measured and recorded by echocardiography and its affiliated software. Generally, FS is range from 25% to 45% is regarded as normal. If FS less than 25%, the patient is suspected to suffered cardiac systolic dysfunction.
• SBP — the SBP is collected at week 0, 6, 12 and 24.
  systolic blood pressure was measured by sphygmomanometer. For patients whose SBP is higher than 140mmHg, the patients is regarded as hypertension.
• DBP — the DBP is collected at week 0, 6, 12 and 24.
  diastolic blood pressure was measured by sphygmomanometer. For patients whose DBP is higher than 90mmHg, the patients is regarded as hypertension.

Trial sites (1)

More The University of Hong Kong-Shenzhen Hospital trials in China

Other trials for the same condition